Molab is a biotechnology research company that utilizes an end-to-end discovery platform combining in-silico design, AI/ML methods, and wet lab validation to optimize small molecule drug development. Their technology accelerates hit-to-lead and lead optimization projects by 1.5 to 2 times through proven ADMET predictions and generative molecular design, addressing the inefficiencies in traditional drug discovery processes.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional small molecule drug discovery is a slow and inefficient process, often hampered by inaccurate predictions of drug efficacy, safety, and pharmacokinetic properties. Optimizing molecules for potency, selectivity, and ADMET (absorption, distribution, metabolism, excretion, and toxicity) characteristics requires extensive experimental validation, leading to high costs and long development timelines.
Solution
Molab provides an end-to-end drug discovery platform that integrates in-silico design and evaluation with wet lab validation to accelerate the development of optimized small molecule drugs. The platform leverages AI/ML methods and physics-based simulations to identify optimal binding sites and modes of action. It screens ultra-large virtual libraries, predicts ADMET properties, and uses generative molecular design to create novel molecular structures with enhanced potency, selectivity, and desirable ADMET profiles. This integrated approach enables faster hit-to-lead and lead optimization, reducing the time and cost associated with traditional drug discovery.
Target Audience
Molab's primary customers are biotechnology and pharmaceutical companies involved in small molecule drug discovery, as well as research institutions seeking to accelerate their drug development programs.
Features
- End-to-end discovery platform integrating in-silico design, AI/ML, and wet lab validation
- Simulation-based identification of optimal binding sites and modes of action
- Ultra-large virtual library screening using AI/ML and physics-based methods
- In-silico ADMET prediction engine with a reliable confidence indicator
- GenAI-powered compound optimization suite for novel molecular structures
- Actionable recommendations based on ADMET predictions
- Compound optimization for potency, selectivity, and ADMET properties